m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03178)
Name
ZANOTERONE
Synonyms
ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-
    Click to Show/Hide
Status
Phase 3
Structure
Formula
C23H32N2O3S
InChI
1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1
InChIKey
MHDDZDPNIDVLNK-ZGIWMXSJSA-N
PubChem CID
9844827
TTD Drug ID
D04NNJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Androgen receptor (AR)
ETS-related transcription factor Elf-3 (ELF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Androgen receptor (AR) is a therapeutic target for ZANOTERONE. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of ZANOTERONE through regulating the expression of Androgen receptor (AR). [1], [2]
References
Ref 1 ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.
Ref 2 Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.